Paradigm Shift Coming for Early NSCLC?

]]>(MedPage Today) -- Patients with operable EGFR-positive non-small cell lung cancer (NSCLC) lived twice as long without disease recurrence when they received osimertinib (Tagrisso) after surgery, according to results of a potentially paradigm-changing...